Preclinical Evaluation of Multivalent Vaccine Combinations Against Shigella and Salmonella

A supplementary document details a preclinical study evaluating a novel combination vaccine strategy. The 833.5 KB DOCX file, authored by Roberta Di Benedetto and licensed under CC-BY-4.0, was last updated on April 22, 2026. It describes a tetravalent Shigella GMMA vaccine co-formulated with a bivalent Salmonella glycoconjugate vaccine.

Use Cases

• Evaluating immunogenicity of multivalent vaccine combinations based on the described GMMA and glycoconjugate antigens.
• Assessing technical feasibility of co-formulating Shigella and Salmonella antigens mentioned in the description.
• Investigating carrier function for bacterial O-antigens based on the described use of Shigella GMMA for S. Paratyphi A.

Strengths

• The document is licensed under the permissive CC-BY-4.0 license.
• It was last updated on April 22, 2026, indicating recent maintenance.

Limitations

• The dataset is a 833.5 KB DOCX file, which is a very small text document, not a structured data collection.
• Row count and column-level documentation are absent; data semantics must be inferred from the narrative text.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Freshness

Last updated 2026-04-22 05:49:49